CytoDyn Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers
CYTODYN INC (CYDY)
NASDAQ:AMEX Investor Relations:
ir.cytodyn.com
Company Research
Source: GlobeNewswire
VANCOUVER, Washington, Feb. 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it has filed a Phase 2 protocol for a basket trial with the U.S. Food and Drug Administration (FDA) under its cancer IND. The Company can immediately initiate enrollment in this Phase 2 clinical trial for the treatment of approximately 22 different solid tumor cancers, including melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications. The Company expects to receive preliminary results on each patient within 3 to 4 weeks after the initial treatment with leronlimab. The Company will continue to enroll patients in its metastatic breast cancer trials. The basket trial is a Phase 2 study with 30 patients with CCR5+ l
Show less
Read more
Impact Snapshot
Event Time:
CYDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYDY alerts
High impacting CYTODYN INC news events
Weekly update
A roundup of the hottest topics
CYDY
News
- CytoDyn Announces FDA Has Lifted Clinical Hold [Yahoo! Finance]Yahoo! Finance
- CytoDyn Announces FDA Has Lifted Clinical HoldGlobeNewswire
CYDY
Sec Filings
- 4/16/24 - Form 424B3
- 4/16/24 - Form 424B3
- 4/15/24 - Form 10-Q
- CYDY's page on the SEC website